RxDoctor Payments Data

Bryan Barnes, APRN

Family · Lawton, OKNPI 1821427576

Payments from drug & device makers

$265in general payments, 2019–2025

Across 15 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Xeris Pharmaceuticals, Inc.$43
  • GSK$33
  • AbbVie$26
  • Sanofi Pasteur Inc.$25
  • Averitas Pharma Inc.$23
  • Lilly USA, LLC$22
  • plus $93 from 6 others

What the payments were for

  • Food & beverage$265100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$265 in reported general payments places this provider in the 45th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$7,081
Medicare patients
70
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin52$45,277
EliquisApixaban46$43,644
Spiriva RespimatTiotropium Bromide42$29,294
FarxigaDapagliflozin Propanediol20$20,696
OzempicSemaglutide16$16,765
JanuviaSitagliptin Phosphate21$16,151
Spiriva HandihalerTiotropium Bromide20$13,217
TrulicityDulaglutide12$12,521
Breo ElliptaFluticasone/Vilanterol31$11,868
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,541
Albuterol Sulfate HfaAlbuterol Sulfate211$7,092
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,640
Gabapentin192$2,503
Ventolin HfaAlbuterol Sulfate23$2,295
Atorvastatin Calcium268$1,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$43,64446 claims
GSKBreo Ellipta, Trelegy Ellipta$33$22,41048 claims
AstraZenecaFarxiga$16$20,69620 claims
Lilly USA, LLCTrulicity, Humulin 70-30$22$14,00923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,026 family providers in Oklahoma.

Other family in Lawton

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →